Abstract
Bacillus Calmette-Guerin (BCG) intravesical therapy has been confirmed its value in reducing the recurrent rate of superficial bladder cancer and in inducing the remission of carcinoma in situ. For better understanding the mechanism of BCG on bladder cancer, we have devoted some studies using the MBT-2 tumor cells and C3H/HeN mice models. Our primitive results demonstrated: 1.Only appropriate dose of BCG-tumor cells mixture could induce the suppression of implanted tumor growth. 2. BCG could attach to the cell membrane of MBT-2 tumor cell. The bacteria-tumor cells adhesion is correlated to its antitumor activity. 3. There is no evidence of cytotoxicity or change the growth rate of MBT-2 tumor cells when it is cocultured with BCG. 4. Implantation of BCG-tumor cells mixture in one site of animal could prevent the rumor growth not only in the original site but also in the other site. These findings imply that direct contact of BCG to the tumor cells might induce strong systemic immunity enough to suppress the growth of implanted tumors.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
